🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

MNOV MNOV

Company Profile ↓
$1.33
-1.48% 1Y
P/E-5.54
52W High$1.88
52W Low$1.18
EPS (TTM)$-0.24

Company Overview

MNOV (MNOV) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -59.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -20.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-20.08%
1 Year:-59.03%

Stock Price Performance

1 Year:-1.48%
6 Months:-18.90%
3 Months:-5.67%
1 Month:-7.64%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 21% of range
$1.18 $1.88
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)48.32 · Neutral
Price Performance
1M-7.64%
3M-5.67%
6M-18.90%
1Y-1.48%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -20.1% CAGR over 5 years.
  • Trading 29.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-5.54
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-20.08%
Profit 5Y
-
Revenue (YoY)
-59.03%
Earnings (YoY)
-

Profitability & Returns

ROCE
-31.77%
ROE
-28.85%
ROA
-26.31%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$-0.24

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$42.70M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.88%
Chg in Prom Hold
-
FII / Inst Holding
11.05%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$409.66K
EBITDA
-
Free Cash Flow
$-9.81M
Operating Cash Flow
$-9.81M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ------------------------4.00M-37.50K-----1.00M----134.60K123.32K186.98K
Operating Income -2.35M--2.21M-2.28M-1.59M--3.39M-3.20M-2.84M--3.02M-2.80M-3.79M--4.67M-3.40M-7.03M--4.98M-4.18M-2.65M-2.92M-4.51M-3.73M-201.53K-4.31M-3.60M-3.41M-4.09M-3.90M-2.96M-3.30M-1.15M-3.14M-3.05M-3.31M-3.20M-3.61M-3.38M-2.84M
Net Income -2.34K-2.38K-2.21K-2.29K-1.61K-2.73K-3.38K-3.20K-2.84K-1.45K-3.02M-2.79M-3.75M-1.60M-4.54M-3.14M-6.78M-208.00K-4.70M-3.88M-2.38M-2.71M-4.45M-3.70M-187.80K-4.28M-3.58M-3.39M-4.03M-3.65M-2.92M-2.87M-723.11K-2.75M-2.63M-2.85M-2.86M-3.28M-3.05M-2.59M
Diluted EPS --------------------------0.09-0.07-0.07-0.08-0.07-0.06-0.06-0.01-0.06-0.05-0.06-0.06-0.07-0.06-0.05
R&D Expense 800.00K-600.00K700.00K500.00K-1.00M900.00K800.00K-800.00K800.00K1.20M-1.60M1.30M2.30M-1.50M1.40M1.10M1.20M2.10M2.10M2.00M2.30M2.00M2.00M2.50M2.40M1.40M1.60M700.00K1.70M1.50M1.80M1.70M2.00M1.50M1.20M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------802.58K--------4.04M-1.00M-409.66K
Operating Income -----21.24M-17.88M-16.11M-10.95M-4.02M-9.22M-8.82M-10.88M-13.03M-15.59M-14.03M-14.18M-10.22M-14.63M-9.90M-12.68M-13.28M
Net Income -25.69M-35.69M-48.90M-21.92M-20.37M-20.19M-17.73M-10.96M-4.03M-9.20M-8.85M-10.87M-11.16M-14.68M-12.94M-13.85M-10.13M-14.07M-8.57M-11.05M-12.00M
Diluted EPS -----------------0.21-0.29-0.17-0.23-0.24
R&D Expense ----10.87M9.71M7.78M4.50M2.70M2.90M2.70M3.10M3.90M5.30M5.70M7.10M8.10M8.70M5.30M6.80M6.70M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2000Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ----------72.93M30.79M19.57M29.55M27.27M37.91M39.81M43.42M77.22M79.21M75.42M87.41M74.15M66.27M55.88M45.60M
Total Equity 4.85M8.05M1.12M4.57M7.67M135.71M100.98M66.61M48.04M40.01M24.70M23.50M14.88M25.43M22.01M32.75M34.53M38.64M73.11M74.89M71.33M83.68M70.24M62.38M52.50M41.59M
Cash & Equivalents --------19.30M19.24M28.25M15.09M4.01M6.70M11.67M22.08M24.12M27.99M62.31M63.79M60.04M71.43M18.51M51.00M40.36M30.81M
Long Term Debt ----------9.48M---------------
Total Liabilities ----------48.23M7.29M4.69M4.12M5.26M5.15M5.28M4.78M4.12M4.31M4.09M3.73M3.91M3.89M3.37M4.02M
Current Liabilities ----------36.79M3.70M1.04M460.44K1.59M1.49M1.63M2.88M2.19M2.23M2.19M2.83M3.19M3.28M2.96M3.80M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.01M-17.70M-13.31M-11.86M-10.65M---6.55M-6.92M-9.11M-9.12M-10.83M-9.38M-12.91M-7.43M-10.64M-9.81M
Investing Cash Flow -1.14M27.64M-6.08K-763.38K-36.75K---84.48K-626.32K-11.27K-36.49K-28.73K-40.01M39.91M-697-2.90K
Financing Cash Flow 18.09M-926.65K155.66K1.55M13.37M--8.67M10.80M42.81M10.62M7.11M20.78M7.92K-0244.02K
Capital Expenditure -16.45K-18.56K-6.08K-83.38K-41.55K-3.52K-2.32K-84.48K--10.20K-11.27K-36.49K-28.73K-5.01K-21.30K-895-2.90K
Free Cash Flow -17.03M-17.72M-13.31M-11.95M-10.69M---6.63M--9.12M-9.14M-10.86M-9.41M-12.92M-7.45M-10.64M-9.81M
Share Buybacks -81.97K-37.46K-8.23K-58.62K-------------

Ratios (Annual)

Figures in %.

Metric Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------------
Operating Margin % --------1,363.8%---------253.0%--990.0%--3,242.5%
Net Margin % --------1,365.8%---------251.0%--857.2%--2,928.8%
ROE % -18.9%-35.3%-73.4%-45.6%-50.9%-81.7%-75.5%-73.7%-15.8%-41.8%-27.0%-31.5%-28.9%-20.1%-17.3%-19.4%-12.1%-20.0%-13.7%-21.0%-28.9%
ROCE % ------49.5%-59.5%-59.1%-13.8%-35.9%-24.2%-28.5%-32.1%-20.8%-18.2%-19.4%-12.1%-20.6%-15.7%-24.0%-31.8%

Shareholding Pattern

Insiders
2.88%
Institutions
11.05%
Public Float
11.38%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MNOV

Yahoo Finance Wed, 15 Jul 2026

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced tha…

Yahoo Finance ue, 30 Jun 2026

MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shar…

Yahoo Finance Mon, 08 Jun 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

The alcohol use disorder market is set to grow due to unmet clinical needs, limited efficacy of current therapies, and rising demand for better-tolerated treatments. Expanding label indications, new regulatory approvals of therapies such as…

Yahoo Finance Mon, 08 Jun 2026

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that…

Yahoo Finance ue, 26 May 2026

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the …

Yahoo Finance Sat, 16 May 2026

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

MNOV — Frequently Asked Questions

What is the current share price of MNOV?

As of 2026-08-05 17:25 PDT, MNOV trades at $1.33 on NASDAQ/NYSE. Its 52-week range is $1.18 to $1.88.

What is the P/E ratio of MNOV?

MNOV trades at a trailing price-to-earnings (P/E) ratio of -5.54.

What is the return on equity (ROE) of MNOV?

MNOV has a return on equity (ROE) of -28.85%. Its return on capital employed (ROCE) is -31.77%.

Is MNOV a good stock to buy?

This page provides a data-driven analysis of MNOV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space